A modern-era use as a dietary supplement developed in the late 1970s after researchers were isolating lovastatin from "Aspergillus" and monacolins from "Monascus", respectively, the latter being the same fungus used to make red yeast rice. Chemical analysis soon showed that lovastatin and monacolin K were identical. Different strains of "Monascus" fungus will produce different amounts of monacolins. The 'Went' strain of "Monascus purpureus" (purpureus = dark red in Latin), when properly fermented and processed, will yield a dried red yeast rice powder that is approximately 0.4% monacolins, of which roughly half will be monacolin K. The two isolations, documentations and patent applications occurred months apart. Lovastatin became the patented, prescription drug Mevacor. Red yeast rice went on to become a non-prescription dietary supplement in the United States and other countries. In 1998, the U.S. Food and Drug Administration (FDA) initiated action to ban a dietary supplement containing red yeast rice extract. The FDA position was that red yeast rice products that contain monacolin K are identical to a prescription drug and, thus, subject to regulation as a drug. The U.S. District Court in Utah ruled in favor of allowing the product to be sold without restriction. This decision was reversed on appeal to the U.S. Court of Appeals in 2001.